Tamoxifen-stimulated growth of breast cancer due to p21 loss - Wikidata - wikimedia - TriplyDB

Tamoxifen-stimulated growth of breast cancer due to p21 loss

Tamoxifen-stimulated growth of breast cancer due to p21 loss

http://www.wikidata.org/entity/Q36423493

about

FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation Regulation of hormonal therapy resistance by cell cycle machinery.14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer.ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.Dual regulatory roles of human AP-endonuclease (APE1/Ref-1) in CDKN1A/p21 expression Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.Ethanol impairs estrogen receptor signaling resulting in accelerated activation of senescence pathways, whereas estradiol attenuates the effects of ethanol in osteoblasts.FKBPL: a marker of good prognosis in breast cancer.Androgen receptor as a targeted therapy for breast cancer.Reinforcing targeted therapeutics with phenotypic stability factors Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.P21 and p27: roles in carcinogenesis and drug resistance.Omics and therapy - a basis for precision medicine.Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system.CtIP is required for DNA damage-dependent induction of P21.MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression.The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.Chromatin landscape and endocrine response in breast cancer.Understanding Lunasin's biology and potential as a cancer therapeutic by utilizing Drosophila genetics.Biological relevance of Hsp90-binding immunophilins in cancer development and treatment.Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells.p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines.

P2860

Q24319845-5835173E-83AC-4D71-86FC-B3CAA111D63E Q24594804-55F97406-7579-49E4-AA1E-AC3649C54D61 Q28588630-90F8C763-BA3F-41E5-8E50-AB2E021B5E74 Q33635621-7949A48D-6AC1-430C-A7A2-180F6D81F4AD Q33705055-DA6E3C01-AABD-4455-808E-34093345EB35 Q33836140-343621FA-5D18-4D15-8A8A-0D24E4290F97 Q34438994-3EF1E070-EB93-4C04-9C3A-017090F9526A Q34559124-66E9545E-D9A3-4089-8C3D-36F1287918B9 Q34708926-09A8249C-3530-45C3-B583-89612E7C7FCC Q34848804-98030175-4FF2-4A52-997C-573F5C75CC07 Q34908845-226511AE-FDC6-4F49-AA0E-A9D7BB4CACBD Q34984068-B6CA4A13-EC84-4520-BA1D-FE57E604FB41 Q35155664-06C6426A-6D8D-4445-BB0B-AD5795BCF376 Q35172941-D500E466-A4AE-4979-A745-D507B22BBD9F Q35470405-23F50C87-27CE-45B3-88EF-8AC56278AACA Q35484712-5D29407C-7F09-463D-9260-7510D8B52A91 Q35558138-3AC1D1BA-5535-4EA9-A069-24F31B21669A Q35666599-42B00EDA-592C-4B72-8120-D33CB4FDCE57 Q35747409-01DDF0C7-DD1E-41F6-8EC2-35E2B48ECEC0 Q35828542-80EFFE9D-CA6E-4961-8B1E-FF1385BB1D99 Q36135807-79B3E641-7C8D-4645-8A37-B303B6C987D7 Q36187514-4C5C4D71-8A8E-4EE2-82AF-69376D201C3F Q36269713-C0828D12-03AC-4346-B07D-1D912412FB72 Q36283422-C6236510-65D7-4C1A-B4CC-BE4D36F257D5 Q37156496-85495DCC-589A-4D89-B5CD-35DE7D09A7A1 Q37184060-8B2EF890-B0DF-481C-BA2F-01C93CADD11C Q37188017-6AC39DA5-69CF-4317-A5F1-A17EE148FA0D Q37527497-E47F397B-92A8-40CF-9A4C-04B026F4F8F8 Q37587039-F1B416FD-C86E-4C0C-9C91-E6C00405728A Q37700939-55E6C9E4-0FD5-428E-82DB-A3F758A1A708 Q37856424-0324354F-1712-4B4C-B24C-1E0375B73BD2 Q38067765-69CC5C31-8FF2-4C7F-A28D-8ECB5265ADCF Q38195673-2562E778-C541-4E64-A63C-F487DA8AA494 Q38371280-7FA9A7E7-DD92-49A3-A02B-4DA4E50BBCE3 Q38706936-EF23A203-61A4-4B8F-B51B-2BA205D82BE5 Q38716747-C870642E-4164-471F-83B8-EECEF532921A Q38794217-C00A179E-1794-42C8-96AC-BC39A62591F3 Q39564939-51E02000-565B-4103-9E35-C340C347B14F Q39692880-1CDA0108-AB72-4EBC-AA1A-427D43AF0B19 Q42364417-FA4AC736-B0B4-4ADE-9271-DBF7C3369864

P2860

Tamoxifen-stimulated growth of breast cancer due to p21 loss

http://www.wikidata.org/entity/Q36423493

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Tamoxifen-stimulated growth of breast cancer due to p21 loss

@ast

Tamoxifen-stimulated growth of breast cancer due to p21 loss

@en

type

label

Tamoxifen-stimulated growth of breast cancer due to p21 loss

@ast

Tamoxifen-stimulated growth of breast cancer due to p21 loss

@en

prefLabel

Tamoxifen-stimulated growth of breast cancer due to p21 loss

@ast

Tamoxifen-stimulated growth of breast cancer due to p21 loss

@en

P1433

Q36423493-2C23BDAA-C33B-411D-87D6-199B60A60301

P1476

Q36423493-8D908281-46C8-4035-BE9F-B2C5E586C1F7

P2093

Q36423493-14D2E4BE-6F01-4FC7-93D9-BF86EE87249E

Q36423493-150945F3-7E87-4340-A000-937E2088D629

Q36423493-351A76AF-45FB-489D-9C4F-764EEAEB1FA4

Q36423493-3E6478B6-FEAD-42B6-AC4B-00265DE06C0E

Q36423493-503965FE-81C1-4DAB-B583-721525A4984C

Q36423493-51A5499B-5080-4DF6-8166-B1822556BA4A

Q36423493-6F38C7EC-95A6-47FE-8284-D5AE1E143A63

Q36423493-705AEF21-9AB8-471A-8D4C-51ABE841CFAA

Q36423493-73F37F55-6A72-4309-A6AE-B08E7521856A

Q36423493-876AA6B9-D54A-4772-9E40-C9892A05BD1F

P2860

Q36423493-050EC86C-2755-4C5D-879E-24979589669D

Q36423493-077F534E-554C-4021-935A-C4E18B70E404

Q36423493-0EAFB31C-9358-40F9-8963-F88DC7BF408E

Q36423493-1B85366F-8892-41E5-9F66-3549D80348AA

Q36423493-24B9E1BA-7248-4A43-A408-B4A3D3840BDF

Q36423493-35260ACA-DF03-45B3-B804-FE9856043423

Q36423493-41DA75AC-CA5A-44BB-80FF-2B114B8AA87A

Q36423493-422FCCA1-E910-4B34-A98C-6834CB51BBF3

Q36423493-49307346-9E02-4002-9E11-55ADD92D7EEF

Q36423493-4EAAAC9B-2A2C-4DCE-BA8D-F0D2607DF90E

P304

Q36423493-28B6C7A5-427C-442F-B097-E71D4EF542AC

P31

Q36423493-E19CB027-C280-4768-B817-CF1E6536ED22

P356

Q36423493-D2FABB6B-D476-4093-BD03-F6C39A3E0A17

P407

Q36423493-DED82AE5-D3B0-46C9-9876-A82F7305FA92

P433

Q36423493-EE0F72F5-61D5-487E-9BB1-D5BADE030362

P478

Q36423493-AA0273BE-C508-4C44-A8D3-09CDC319517E

P50

Q36423493-59C0C96B-0B42-4489-8537-FAA9534B62B0

Q36423493-FEB144DB-3196-4880-9788-A207D9945AA0

P577

Q36423493-8E4F9B7D-5C38-45A2-A680-69A00FFDE06F

P5875

Q36423493-2770F994-3535-4C9D-9974-98883AD16AE9

P698

Q36423493-918D80A1-6984-4A9F-A7E9-92D9BED3D062

P932

Q36423493-FA8F6819-1725-4B91-A42F-A19FDFAFDE92

P356

PNAS.0710887105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Tamoxifen-stimulated growth of breast cancer due to p21 loss

@en

P2093

Abde M Abukhdeir

http://www.w3.org/2001/XMLSchema#string

Angelo M De Marzo

http://www.w3.org/2001/XMLSchema#string

Bedri Karakas

http://www.w3.org/2001/XMLSchema#string

Ben Ho Park

http://www.w3.org/2001/XMLSchema#string

Brian G Blair

http://www.w3.org/2001/XMLSchema#string

Courtney Pendleton

http://www.w3.org/2001/XMLSchema#string

Elizabeth Garrett-Mayer

http://www.w3.org/2001/XMLSchema#string

Hetty Carraway

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Konishi

http://www.w3.org/2001/XMLSchema#string

John P Gustin

http://www.w3.org/2001/XMLSchema#string

P2860

p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2

Gfi1 coordinates epigenetic repression of p21Cip/WAF1 by recruitment of histone lysine methyltransferase G9a and histone deacetylase 1

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis

Site-directed mutagenesis by overlap extension using the polymerase chain reaction

The consensus coding sequences of human breast and colorectal cancers

WAF1, a potential mediator of p53 tumor suppression

Molecular determinants for the tissue specificity of SERMs

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

P304

288-293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0710887105

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5686095

http://www.w3.org/2001/XMLSchema#string

P698

18162533

http://www.w3.org/2001/XMLSchema#string

P932

2224203

http://www.w3.org/2001/XMLSchema#string